TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding TScan Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 28 | 28 | 0 |
| Shares | 9.67M | 28.0M | +18.3M (+189.1%) |
| Value | $20.3M | $69.9M | +$49.6M (+244.1%) |
New holders (5)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynx1 Capital Management LP | 5,224,600 | $13.1M | 8.56% |
| EcoR1 Capital, LLC | 5,000,000 | $12.5M | 0.33% |
| BVF Inc | 2,989,474 | $7.47M | 0.21% |
| Monashee Investment Management LLC | 400,000 | $1.00M | 0.24% |
| Stifel Financial Corp | 99,000 | $247.5K | 0.00% |
Sold out (5)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Newtyn Management, LLC | 236,800 | $497.3K |
| Cannell Capital LLC | 14,666 | $30.8K |
| LPL Financial LLC | 12,000 | $25.2K |
| Tower Research Capital LLC (TRC) | 4,147 | $9.00K |
| Advisor Group Holdings, Inc. | 1 | $2 |